You are here: Industry Insights > HFB30132A

News List

HiFiBiO, Pharmsynthez and IBCh sign Covid-19 antibody development deal pharmaceutical-technology
November 25, 2020
HiFiBiO Therapeutics has entered into a partnership with Pharmsynthez and Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry RAS (IBCh) to develop and commercialise its SARS-CoV-2 neutralising antibody, HFB30132A, for Covid-19 treatment.
HiFiBiO completes first cohort of phase 1 study of SARS-CoV-2 neutralising antibody pharmaceutical-business-review
October 29, 2020
HiFiBiO Therapeutics announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment and prevention of COVID-19.
HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19 pharmaceutical-business-review
September 17, 2020
HiFiBiO Therapeutics has entered into a partnership with South Korea-based ABL Bio to co-develop its SARS-CoV-2 neutralising antibody HFB30132A for the treatment of Covid-19.
HiFiBiO submits IND application for SARS-CoV-2 neutralising antibody to treat Covid-19 patients pharmaceutical-business-review
August 31, 2020
HiFiBiO Therapeutics announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for a novel SARS-CoV-2 neutralizing antibody for the treatment of Covid-19 patients.